secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001493152-23-002918
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte applies to transfer Nasdaq listing to Capital Market to cure bid price deficiency
--------------------------------------------------------------------------------

- Applied on Jan 24, 2023 to transfer listing from Nasdaq Global Market to Nasdaq Capital Market.
- Transfer expected to allow additional 180-day compliance period for minimum bid price requirement.
- Common stock to continue trading under symbol "OCX" after transfer.
- Previously received Nasdaq deficiency notice on Aug 9, 2022 for bid price below $1.00 for 30 consecutive days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223002918/0001493152-23-002918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223002918/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer